Hony Capital trims stake in CSPC Pharmaceutical by $154 million

The upsized deal comes at a 10.2% discount and will open the door for the private equity firm to convert part of an $860 million CB following a surge in the share price.

A company controlled by Chinese private equity firm Hony Capital last night sold part of its stake in Hong Kong-listed CSPC Pharmaceutical, raising HK$1.2 billion $154 million.

While it didn’t spell it out directly, the sale is likely to have been prompted by a desire to convert some of its CSPC Pharma convertible bonds after the share price has rallied 80% this year. According to the conditions, the CB can only be converted into shares if the free-float remains above the required 25% and since the free-float is currently 25.2% Hony needed to reduce its existing holdings first.

The vendor offered to sell a 10.2%...

¬ Haymarket Media Limited. All rights reserved.

FinanceAsia has updated its subscription model.

Registered readers now have the opportunity to read 5 articles from our award-winning website for free.

To obtain unlimited access to our award-winning exclusive news and analysis, we offer subscription packages, including single user, team (2-10 users), or office-wide licences.

To help you and your colleagues access our proprietary content, please contact us at subscriptions@financeasia.com, or +(852) 2122 5222

Article limit is reached.

Hello! You have used up all of your free articles on FinanceAsia.

To obtain unlimited access to our award-winning exclusive news and analysis, we offer subscription packages, including single user, team (2-10 users), or office-wide licences. To help you and your colleagues access our proprietary content, please contact us at subscriptions@financeasia.com, or +(852) 2122 5222